759 related articles for article (PubMed ID: 27096405)
1. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
2. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
[TBL] [Abstract][Full Text] [Related]
3. Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment.
Modi A; Tang J; Sen S; Díez-Pérez A
Curr Med Res Opin; 2015 Apr; 31(4):767-77. PubMed ID: 25708648
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan.
Fu SH; Wang CY; Yang RS; Wu FL; Hsiao FY
J Bone Joint Surg Am; 2017 Jun; 99(11):938-946. PubMed ID: 28590379
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate use after clinical fracture and risk of new fracture.
Bergman J; Nordström A; Nordström P
Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
[TBL] [Abstract][Full Text] [Related]
6. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for fracture among current, persistent users of bisphosphonates.
LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
[TBL] [Abstract][Full Text] [Related]
9. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
11. Association of Bisphosphonate Use and Risk of Revision After THA: Outcomes From a US Total Joint Replacement Registry.
Khatod M; Inacio MC; Dell RM; Bini SA; Paxton EW; Namba RS
Clin Orthop Relat Res; 2015 Nov; 473(11):3412-20. PubMed ID: 25896134
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative.
Drieling RL; LaCroix AZ; Beresford SAA; Boudreau DM; Kooperberg C; Chlebowski RT; Ko MG; Heckbert SR
J Am Geriatr Soc; 2017 Sep; 65(9):1924-1931. PubMed ID: 28555811
[TBL] [Abstract][Full Text] [Related]
13. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
14. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
[TBL] [Abstract][Full Text] [Related]
15. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
16. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.
Kang JH; Keller JJ; Lin HC
Osteoporos Int; 2012 Oct; 23(10):2551-7. PubMed ID: 22270858
[TBL] [Abstract][Full Text] [Related]
17. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing?
Ha KY; Park KS; Kim SI; Kim YH
Osteoporos Int; 2016 Feb; 27(2):483-8. PubMed ID: 26202489
[TBL] [Abstract][Full Text] [Related]
18. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults.
Solomon DH; Hochberg MC; Mogun H; Schneeweiss S
Osteoporos Int; 2009 Jun; 20(6):895-901. PubMed ID: 18843515
[TBL] [Abstract][Full Text] [Related]
19. Analysis of osteoporosis treatment patterns with bisphosphonates and outcomes among postmenopausal veterans.
LaFleur J; DuVall SL; Willson T; Ginter T; Patterson O; Cheng Y; Knippenberg K; Haroldsen C; Adler RA; Curtis JR; Agodoa I; Nelson RE
Bone; 2015 Sep; 78():174-85. PubMed ID: 25896952
[TBL] [Abstract][Full Text] [Related]
20. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
